Article

FDA approves generic postop inflammation drug

The FDA has granted final approval for Hi-Tech Pharmacal Co. Inc.’s Abbreviated New Drug Application for its bromfenac ophthalmic solution, 0.09% (once-a-day).

 

Amityville, NY-The FDA has granted final approval for Hi-Tech Pharmacal Co. Inc.’s Abbreviated New Drug Application for its bromfenac ophthalmic solution, 0.09% (once-a-day).

The drug-which is the generic form of ISTA Pharmaceuticals’ Bromday ophthalmic solution, 0.09%-is used to treat postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Hi-Tech plans to launch the product immediately.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
© 2025 MJH Life Sciences

All rights reserved.